CHEMBIO DIAGNOSTICS INC (CEMI)
US1635722093 - Common Stock
Life Science Outsourcing, Inc. Welcomes Neil A. Goldman as Chief Financial Officer
/PRNewswire/ -- Life Science Outsourcing, Inc. ("LSO"), a premier contract manufacturer and value-added service provider for the medical device and life...
Biosynex Completes Acquisition of Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE...
Shareholder Alert: Ademi LLP investigates whether Chembio Diagnostics, Inc. has obtained a Fair Price in its transaction with Biosynex
/PRNewswire/ -- Ademi LLP is investigating Chembio (NASDAQ: CEMI) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023
Failure to tender shares could result in the termination of the proposed merger between Chembio and Biosynex...
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and...
Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023
MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on...
Chembio’s CEO Letter to Stockholders
Reminder to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023...
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
STRASBOURG, France, March 29, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and...
Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023
MEDFORD, N.Y., March 21, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on...
Chembio Announces Letter to Stockholders Regarding Tender Offer
MEDFORD, N.Y., March 15, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on...
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
STRASBOURG, France, March 15, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and...
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CINC, DCT, ANGN, CEMI
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Moore Kuehn Encourages ALR, CEMI, LPTX, and ATCX Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another look at the biggest pre-market stock movers worth checking out as we start off trading early on Wednesday!
Biosynex to buy Chembio Diagnostics (NASDAQ:CEMI) in $17.2M deal
Biosynex has entered into a deal with Chembio Diagnostics (CEMI) under which Biosynex will acquire Chembio in an all-cash transaction valued at $17.2M. Read more on the deal here.
Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement
Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing,...
Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System
HAUPPAUGE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on...
Chembio Diagnostics Reports Third Quarter 2022 Financial Results
HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care...
Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022
HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on...